Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients.
OBJECTIVE
Egyptian hepatocellular carcinoma (HCC) patients present at advanced stages. We aimed to study the influence of surveillance versus non-surveillance on HCC staging and the potential therapeutic options.


METHODS
A retrospective study to evaluate the effect of surveillance on early detection of HCC among cirrhotic patients from 2003 to 2008. Patients examined every 6 months using ultrasound and α-fetoprotein (α-FP) (group A) and those diagnosed with those that present for the first time symptomatically or incidentally (group B). Groups were compared for α-FP level, tumour characteristics, severity of liver disease; tumour staging was evaluated by Okuda, CLIP and BCLC staging systems, in addition to the potential therapeutic options.


RESULTS
Group A comprised 122 HCC cases and group B 473. Surveillance improved HCC detection: at the stage of single nodule in 62.3% in group A versus 52.2% in group B, (P = 0.046) and reduced the percentage of HCC with portal vein thrombosis in 16.4 versus 33.8%, (P = 0.000) and the percentage of α-FP >400 ng/ml in 19.5 versus 32.6%, (P = 0.006) in groups A and B, respectively. Surveillance doubled the detection of HCC at early stage of BCLC (25.4 vs. 11.9% P = 0.000) and doubled the patients' chance for loco-regional ablation (12.3 vs. 5.9%, P = 0.015) and liver transplantation (10.7 vs. 3.2%, P = 0.001) in groups A and B, respectively.


CONCLUSIONS
HCC surveillance increases early detection of HCC and doubled the chances for curative options. Implementation of both HCC surveillance and cadaveric liver transplantation programs should be recommended in Egypt.
El-Zayadi
Abdel-Rahman
AR
Badran
Hanaa M
HM
Shawky
Sherine
S
Emara
Sally
S
El-Bareedy
Ashraf
A
Sobhi
Mohammed
M
Ann Ital Chir. 2008 Mar-Apr;79(2):91-7
18727270
Gastroenterology. 1985 Aug;89(2):259-66
2408960
Int J Cancer. 2001 Oct 15;94(2):290-6
11668511
Hepatogastroenterology. 2008 Mar-Apr;55(82-83):609-14
18613418
Semin Liver Dis. 1999;19(3):329-38
10518312
Hepatology. 1990 Oct;12(4 Pt 1):680-7
1698703
N Engl J Med. 1999 Mar 11;340(10):745-50
10072408
J Hepatol. 2009 Oct;51(4):632-4
19660824
Hepatology. 2000 Feb;31(2):330-5
10655254
J Clin Gastroenterol. 2002 Nov-Dec;35(5 Suppl 2):S138-42
12394217
Ann Oncol. 2003 Oct;14(10):1463-7
14504044
J Hepatol. 2001 Sep;35(3):421-30
11592607
Liver Transpl. 2000 May;6(3):320-5
10827233
J Hepatol. 1994 Jan;20(1):65-71
7515408
J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22
15042359
Hepatology. 1999 Dec;30(6):1434-40
10573522
J Cancer Res Clin Oncol. 1997;123(6):357-60
9222303
World J Gastroenterol. 2005 Sep 7;11(33):5193-8
16127751
Liver Int. 2006 Jun;26(5):543-51
16761998
N Engl J Med. 1996 Mar 14;334(11):693-9
8594428
J Hepatol. 2008;48 Suppl 1:S20-37
18304676
Gut. 2005 Mar;54(3):411-8
15710992
Hepatol Res. 2008 May;38(5):465-73
18042228
J R Coll Surg Edinb. 2002 Feb;47(1):389-99
11874260
Hepatology. 2000 Oct;32(4 Pt 1):842-6
11003632
Hepatobiliary Pancreat Dis Int. 2008 Jun;7(3):237-57
18522878
Hepatology. 2000 Apr;31(4):840-5
10733537
Hepatology. 2005 Nov;42(5):1208-36
16250051
Cancer. 1985 Aug 15;56(4):918-28
2990661
Int J Cancer. 2001 Oct 15;94(2):153-6
11668491
Lancet. 2003 Dec 6;362(9399):1907-17
14667750
Eur J Cancer Prev. 2001 Feb;10(1):111-5
11263586